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OBJECTIVE—Proinﬂammatory cytokines contribute to sys-
temic low-grade inﬂammation and insulin resistance. Tumor
necrosis factor (TNF)- impedes insulin signaling in insulin
target tissues. We determined the role of inhibitor of nuclear
factor-B kinase (IKK) in TNF-–induced impairments in insu-
lin signaling and glucose metabolism in skeletal muscle.
RESEARCH DESIGN AND METHODS—Small interfering
RNA (siRNA) was used to silence IKK gene expression in
primary human skeletal muscle myotubes from nondiabetic
subjects. siRNA gene silencing reduced IKK protein expression
73% (P  0.05). Myotubes were incubated in the absence or
presence of insulin and/or TNF-, and effects of IKK silencing
on insulin signaling and glucose metabolism were determined.
RESULTS—Insulin increased glucose uptake 1.7-fold (P  0.05)
and glucose incorporation into glycogen 3.8-fold (P  0.05) in
myotubes from nondiabetic subjects. TNF- exposure fully im-
paired insulin-mediated glucose uptake and metabolism. IKK
siRNA protected against TNF-–induced impairments in glucose
metabolism, since insulin-induced increases in glucose uptake
(1.5-fold; P  0.05) and glycogen synthesis (3.5-fold; P  0.05)
were restored. Conversely, TNF-–induced increases in insulin
receptor substrate-1 serine phosphorylation (Ser
312), Jun NH2-
terminal kinase phosphorylation, and extracellular signal–related
kinase-1/2 mitogen-activated protein kinase (MAPK) phosphory-
lation were unaltered by siRNA-mediated IKK reduction.
siRNA-mediated IKK reduction prevented TNF-–induced insu-
lin resistance on Akt Ser
473 and Thr
308 phosphorylation and
phosphorylation of the 160-kDa Akt substrate AS160. IKK
silencing had no effect on cell differentiation. Finally, mRNA
expression of GLUT1 or GLUT4 and protein expression of MAPK
kinase kinase kinase isoform 4 (MAP4K4) was unaltered by IKK
siRNA.
CONCLUSIONS—IKK silencing prevents TNF-–induced im-
pairments in insulin action on Akt phosphorylation and glucose
uptake and metabolism in human skeletal muscle. Diabetes 57:
2066–2073, 2008
S
ubclinical inﬂammation plays a role in the etiol-
ogy of peripheral insulin resistance in type 2
diabetes (1–6). Correlative studies in type 2 dia-
betic patients link excessive levels of the proin-
ﬂammatory cytokine tumor necrosis factor (TNF)- in
adipose tissue (7), blood plasma (8–10), and skeletal
muscle (11) with whole-body insulin resistance (12,13). In
vivo studies provide evidence that an acute infusion of
TNF- into healthy humans rapidly induces skeletal mus-
cle insulin resistance by disrupting insulin signaling to
GLUT4 translocation without altering the hepatic glucose
production (1). Thus, the identiﬁcation and characteriza-
tion of TNF-–sensitive targets may provide insight into
mechanism(s) for the development of peripheral insulin
resistance in response to inﬂammatory stress.
TNF- is principally secreted by activated macrophages
in response to infection and stress. Two unique membrane
receptors, TNF- receptor (TNFR)1 and TNFR2, mediate
the biological effects of TNF- (14). The TNFR1 receptor
subtype transduces TNF- signaling to the transcription
factor nuclear factor-B (NF-B) (14). TNF-–induced
activation of NF-B is mediated by inhibitor of nuclear
factor-B kinase (IKK), a serine kinase involved in the
phosphorylation and subsequent degradation of inhibitor
of nuclear factor-B( I B), which leads to the activation of
the transcription factor NF-B (15–18). IKK has been
implicated in the development of insulin resistance (19).
High doses of salicylates target and inhibit IKK to sen-
sitize insulin signaling and reverse the associated patho-
genic characteristics including hyperglycemia, hyperinsu-
linemia, and dyslipidemia in diabetic mice (3,20). The
proposed mechanism by which salicylates sensitize insulin
signaling to glucose uptake involves inhibition of IKK
(3,20) and enhanced insulin signaling to metabolic end
points (21). Collectively, these data implicate a role for
IKK-mediated events in the pathogenesis of insulin resis-
tance in obesity and type 2 diabetes.
TNF- directly induces insulin resistance in primary
human skeletal muscle cells (22). TNF-–mediated insulin
resistance can be rescued via small interfering RNA
(siRNA)-mediated silencing of mitogen-activated protein
kinase kinase kinase kinase isoform 4 (MAP4K4) (22), an
upstream regulator of Jun NH2-terminal kinase (JNK) and
extracellular signal–related kinase (ERK)1/2 (p42/44 mito-
gen-activated protein kinase [MAPK]) kinase (22–24). In
addition to mediating insulin resistance through the acti-
vation of JNK, TNF- exerts negative effects on insulin
signaling through the serine/threonine kinase IKK in
cultured immortalized cells (25,26) and in animal models
From the
1Department of Molecular Medicine and Surgery, Karolinska Insti-
tutet, Stockholm, Sweden; and the
2Department of Physiology and Pharma-
cology, Karolinska Institutet, Stockholm, Sweden.
Corresponding author: Anna Krook, anna.krook@ki.se.
Received 5 June 2007 and accepted 18 April 2008.
Published ahead of print at http://diabetes.diabetesjournals.org on 28 April
2008. DOI: 10.2337/db07-0763.
© 2008 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
2066 DIABETES, VOL. 57, AUGUST 2008of type 2 diabetes (3). Here, we test the hypothesis that
IKK is an intermediate kinase for TNF- action on
insulin-mediated glucose uptake in primary human skele-
tal muscle cells. We provide evidence that TNF-–induced
insulin resistance on signal transduction at the level of Akt
is prevented by siRNA-mediated silencing of IKK.W e
also show that the TNF-–induced impairments on insulin-
mediated glucose uptake and glycogen synthesis in pri-
mary human myotubes are prevented by IKK inhibition.
Thus, strategies to inhibit IKK expression in human
skeletal muscle may prevent insulin resistance associated
with inﬂammatory stress.
RESEARCH DESIGN AND METHODS
Skeletal muscle biopsies were obtained with informed consent from nondia-
betic individuals (seven male and two female) scheduled for abdominal
surgery. The mean age and BMI of the subjects were 57  2 years and 25.8 
0.9 kg/m
2, respectively. None of the subjects had any known metabolic
disorders, and all presented with normal fasting plasma glucose values (5.5 
0.3 mmol/l). The protocols in this study were approved by the ethics
committee at Karolinska Institutet.
DMEM (Dulbecco’s modiﬁed Eagle’s medium), DMEM F-12, fetal bovine
serum, penicillin, streptomycin, and Fungizone were obtained from Invitrogen
(Stockholm, Sweden). Recombinant human TNF- and general laboratory
reagents were obtained from Sigma (St. Louis, MO), PD98059 was obtained
from Calbiochem (La Jolla, CA), and radioactive reagents were purchased
from Amersham (Uppsala, Sweden).
Cell culture and siRNA transfection. Satellite cells were isolated from
muscle biopsies and cultured as previously described (27). IKK-speciﬁc
siRNA oligos were purchased from Ambion (Austin, TX). Myotubes trans-
fected with oligos against a scrambled sequence (scrambled siRNA) were
used as a control. Myotubes were transfected using Lipofectamine 2000
(Invitrogen, Sweden) as previously described (28).
Western blot analysis. Cells were harvested and protein concentration was
determined using the Pierce method. After protein determination, aliquots of
lysates were mixed with 4 Laemmli-sample buffer, and proteins were
separated by SDS-PAGE. Proteins were visualized by enhanced chemilumi-
nescence and quantiﬁed by densitometry (29). TNF-–induced degradation of
IB was analyzed in lysates by immunoblot analysis with anti-IB (Cell
Signaling, Beverly, MA). Signaling parameters were investigated using phos-
phospeciﬁc antibodies against Akt (Ser
473), Akt (Thr
308), ERK1/2, p42/44
MAPK kinase Thr
202/Tyr
204, stress-activated protein kinase/JNK (Thr
183/185),
glycogen synthase kinase (GSK)-3 (Ser
9), and phospho-Akt Substrate
(RXRXXS/T) (Cell Signaling). Antibodies against phospho–insulin receptor
substrate (IRS)-1 Ser
312 and total IRS-1 were purchased from Upstate (Char-
lottesville, VA). Antibodies against total IKK, Akt, and ERK were from Cell
Signaling. Mitogen-activated protein kinase kinase (MEK) isoform 4
(MAP2K4) and MAP4K4 antibodies were obtained from Abgent (San Diego,
CA), glyceraldehyde-3-phosphate dehydrogenase from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA), and Desmin from Abcam (Cambridge, U.K.).
Glucose uptake and metabolism. Differentiated primary human muscle
myotubes were exposed to saline or TNF- (20 ng/ml) for 2 h. Thereafter,
myotubes were incubated in the absence or presence of insulin (120 nmol/l),
and 2-deoxyglucose uptake or glucose incorporation into glycogen was
determined, as previously described (29). Total protein concentration was
assessed using the Bradford method (Bio-Rad, Richmond, CA). Data are
reported as nmol  mg
1  min
1.
Statistics. Data are presented as means  SEM. Statistical differences were
determined by Student’s t test or ANOVA using Fisher’s least signiﬁcant
differences test for post hoc determination.
RESULTS
IKK silencing in myotubes. The effect of IKK gene
silencing on IKK protein expression was determined in
primary cultured human myotubes. Two days after induc-
tion of the myotube differentiation program, cells were
transfected with siRNA against IKK. Expression of IKK
was unaltered in cells exposed to a scrambled siRNA
sequence or following2ho fincubation with TNF- (Fig.
1A). siRNA against IKK reduced protein expression 73%,
(Fig. 1A)( P  0.05) and mRNA expression by 55% (P 
0.01) (data not shown) compared with cells transfected
with scrambled siRNA. Following TNF- exposure (2 h, 20
ng/ml), protein content of I was reduced (Fig. 1B),
indicating that I was targeted for degradation after
cytokine exposure. siRNA against IKK increased the
basal expression of I and blunted the TNF-–mediated
reduction. Myotube growth and morphology was unal-
tered after IKK silencing (Fig. 2A). Expression of the
FIG. 1. Protein expression of IKK and IB. A: Protein expression of
IKK was unaltered in cells exposed to a scrambled siRNA sequence, a
2-h incubation with TNF- (lanes 1–3). siRNA against IKK reduced
protein expression by 73% (lanes 4 and 5). Glyceraldehyde-3-phos-
phate dehydrogenase (GADPH) expression was determined to control
for equal loading. B:I B was measured after siRNA-mediated deple-
tion of IKK. Results are means  SE. *P < 0.05 vs. transfected
scrambled siRNA (Scr) control (n  4).
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tion (4 days after transfection) was unaltered between
myotubes treated with siRNA against a scrambled se-
quence or IKK (Fig. 2B).
Effect of IKK silencing on glucose uptake and me-
tabolism. We have reported that an acute TNF- exposure
impairs insulin-stimulated glucose uptake and glycogen
synthesis in cultured human skeletal muscle (22). Here, we
determined whether TNF-–induced insulin resistance is
prevented by IKK silencing. Four days after transfection,
glucose uptake (Fig. 3A) and incorporation into glycogen
(Fig. 3B) was assessed under basal and insulin-stimulated
conditions in the presence or absence of TNF-. In control
cells or cells transfected with scrambled siRNA, insulin
(120 nmol/l) increased glucose uptake 1.7-fold (P  0.05)
and glycogen synthesis 3.8-fold (P  0.05). Basal glucose
transport and incorporation to glycogen was unaltered in
cells exposed to TNF-. However, TNF- pretreatment
reduced insulin action on glucose uptake (P  0.05) and
incorporation to glycogen (P  0.05). Silencing of IKK
had no effect on either basal or insulin-stimulated glucose
metabolism. Importantly, siRNA-mediated silencing of
IKK prevented the inhibitory effect of TNF- on insulin-
mediated glucose metabolism.
Effect of IKK silencing on Akt phosphorylation.
Insulin increased Akt Ser
473 and Thr
308 phosphorylation in
primary cultures of human skeletal muscle (Fig. 4A and B,
respectively). Insulin action on Akt was unaltered in cells
transfected with scrambled siRNA. TNF- impaired insulin
action on Akt Ser
473 and Thr
308 phosphorylation (P 
0.05). IKK silencing had no effect on basal (data not
shown) or insulin-stimulated Akt Ser
473 or Thr
308 phos-
phorylation but prevented the TNF-–induced impair-
ment. Protein expression of Akt was unaltered in response
to insulin, TNF-, or gene silencing (Fig. 4C).
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FIG. 2. Myotube growth. A: Morphological appearance of human skeletal muscle myotube formation after introduction of scrambled siRNA or
siRNA against IKK. Photomicrographs are shown at 10 magniﬁcation for myotubes at day 6 of differentiation (4 days after introduction of
siRNA). Results are from two separate experiments. B: Representative immunoblot showing the differentiation marker desmin.
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FIG. 3. Effect of siRNA-mediated silencing of IKK on glucose uptake
and glycogen synthesis. Glucose uptake (A) and glycogen synthesis (B)
were measured in differentiated primary skeletal muscle myotubes
under basal conditions () and after insulin stimulation (f). Results
are means  SE. *P < 0.05 vs. respective basal cells. †P < 0.05 vs.
TNF-– and insulin-stimulated untransfected cells (n  4).
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phorylation. To further evaluate the effect of IKK on
insulin signaling, phosphorylation of the Akt substrates
GSK3 and AS160 was determined. Insulin increased
phosphorylation of GSK3 Ser
9 (Fig. 5A) and AS160 (Fig.
5B) in primary cultures of human skeletal muscle. These
responses were unaltered in cells transfected with scram-
bled siRNA. TNF- treatment increased GSK3 Ser
9 phos-
phorylation to the same extent as insulin but had no effect
on insulin-mediated phosphorylation. Silencing of IKK
had no effect on basal or insulin-stimulated GSK3 Ser
9
and prevented the TNF-–induced increase in GSK3
phosphorylation. TNF- treatment prevented the insulin-
mediated increase in AS160 phosphorylation, and silenc-
ing of IKK restored this insulin effect.
Effect of IKK silencing on ERK 1/2 MAPK phosphor-
ylation. Insulin increased ERK 1/2 MAPK phosphorylation
(P  0.05) in primary cultures of human skeletal muscle
(Fig. 6A–C). Insulin action on ERK 1/2 MAPK was unal-
tered in cells transfected with scrambled siRNA. TNF-
exposure increased basal ERK 1/2 MAPK phosphorylation
(P  0.05), although to a lesser extent than observed in
response to insulin. TNF- exposure did not modify
insulin action on ERK 1/2 MAPK phosphorylation. IKK
silencing had no effect on ERK 1/2 MAPK phosphoryla-
tion either in the absence or presence of insulin and/or
TNF-. Total ERK expression was unaltered in response
to TNF- exposure or siRNA gene silencing. To further
explore the role of ERK in the mediation of TNF-–
induced impairments in insulin-mediated glucose me-
tabolism, we determined the effect of the MEK inhibitor
PD98059 on glycogen synthesis in response to insulin
and TNF- (Fig. 6D). Exposure of primary cultures to
PD98059 reduced insulin and TNF-–mediated ERK1/2
phosphorylation (data not shown). However, this inhib-
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FIG. 4. Akt Ser
473 and Thr
308 phosphorylation. Representative immu-
noblot showing Akt Ser
473 (A) and Akt Thr
308 (B) phosphorylation in
response to insulin and TNF-. C: Total Akt protein expression.
Graphs are summarized data (mean  SE). *P < 0.05% vs. untrans-
fected control cells. †P < 0.05 vs. TNF-–stimulated untransfected
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FIG. 5. GSK-3 and AS160 phosphorylation. Representative immuno-
blot showing pGSK3 Ser
9 (A) and Akt substrate AS160 (B) phosphor-
ylation in response to insulin or TNF- under basal conditions () and
after insulin stimulation (f). Graphs are summarized data (mean 
SE). *P < 0.05 vs. respective basal. †P < 0.05 vs. TNF-–stimulated
untransfected cells. #P < 0.05 vs. control basal (GSK3, n  3; AS160,
n  4).
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insulin or TNF- exposure.
Effect of IKK silencing on JNK phosphorylation.
Insulin increased p54 and p46 JNK phosphorylation (P 
0.05) in primary cultures of human skeletal muscle (Fig.
7). Insulin action on p54 and p46 JNK was unaltered in
cells transfected with scrambled siRNA. Similar to results
noted for ERK1/2 MAPK, TNF- exposure increased basal
p54 and p46 JNK phosphorylation, and IKK silencing had
no effect on JNK phosphorylation either in the absence or
presence of insulin and/or TNF-.
Effect of IKK silencing on IRS-1 gel mobility or
Ser
312 phosphorylation. TNF- exposure is associated
with increased phosphorylation of IRS-1 on Ser
312. Thus,
we determined whether IKK plays a role in TNF-–
mediated IRS-1 Ser
312 phosphorylation in primary human
myotubes. Insulin and TNF- increased IRS-1 Ser
312 phos-
phorylation (Fig. 8A), and this response was unaltered in
cells transfected with siRNA against either a scrambled
sequence or IKK. To evaluate the total phosphorylation
status of IRS-1, a gel mobility shift assay was performed.
Insulin and TNF- induced an upward mobility shift in
IRS-1 migration in SDS-PAGE (Fig. 8B), indicating in-
creased phosphorylation. The effect of insulin on IRS-1
mobility was unaltered in cells transfected with scrambled
siRNA. IKK silencing had no effect on the mobility shift of
IRS-1 in response to either insulin or TNF- exposure.
Thus, IKK does not appear to mediate TNF-–induced
phosphorylation events on IRS-1.
Effect of IKK silencing on mRNA and protein ex-
pression. Gene silencing of IKK did not alter either
GLUT1 or GLUT4 mRNA (105  31 or 87  12%,
respectively, as compared with cells transfected with a
scrambled sequence). Because we have recently re-
ported that MAP4K4 siRNA prevents TNF-–induced
insulin resistance (22), protein expression of MAP4K4 and
the upstream kinase MAP2K4 was also assessed in cells
transfected with siRNA against a scrambled sequence or
IKK. Protein content of either MAP4K4 or MAP2K4 was
unaltered in myotubes transfected with scrambled or IKK
siRNA (data not shown).
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IKK is a core component of the oligomeric IKK complex,
which consists of two catalytic subunits, IKK and IKK,
and a regulatory subunit IKK, or NEMO (16,18,30,31). The
two catalytic subunits share 	50% amino acid sequence
homology, whereas the regulatory subunit does not con-
tain a recognizable catalytic domain (21). Despite the
overall sequence identity between IKK and IKK, these
subunits have specialized roles as mediators of cellular
stress. For example, deletion of IKK (IKK
/) causes
limb deformities (31), whereas deletion of IKK
(IKK
/) is lethal in mouse embryos (32). Of the two
catalytic subunits, IKK is considered to be the main
regulator of NF-B function because of its higher activity
(	30-fold) toward IB (17,33). Recent evidence under-
scores a central role of IKK in insulin sensitivity and type
2 diabetes pathogenesis (2,3,20,21,34,35). High doses of
salicylates, which repress IKK activity, reverse hypergly-
cemia, hyperinsulinemia, and dyslipidemia in obese ro-
dents by increasing insulin sensitivity (2,3,20,21).
Consequently, we determined the role of IKK in insulin
action on glucose uptake using siRNA-mediated gene
silencing. We provide evidence that IKK plays a role in
TNF-–induced impairments in insulin action on Akt sig-
naling and glucose uptake and metabolism in human
skeletal muscle.
TNF- has a biphasic response to NF-B, which is
required for cytokine-induced skeletal muscle damage and
wasting/cachexia (36,37). Cytokines activate the IKK com-
plex, leading to phosphorylation of IB on Ser
32 and
Ser
36. Phosphorylation of these residues causes polyubiq-
uitination and subsequent degradation of IB by proteo-
somes (16). The breakdown of IB leads to the release
and nuclear translocation of NF-B, where it binds to
target genes and drives the expression of cytokines, in-
cluding TNF-, interleukin-6, and interleukin-1 (38).
Here, we report that a 2-h TNF- exposure of cultured
myotubes decreased I protein content, indicating that
I is targeted for degradation after cytokine exposure.
This ﬁnding is consistent with the ﬁrst transient phase of
TNF-–mediated activation of NF-B (37). The siRNA-
mediated reduction of IKK prevented the TNF- effect on
I degradation. Skeletal muscle wasting/cachexia, due
to accelerated protein degradation through ubiquitin-de-
pendent proteolysis, occurs in a manner analogous to
IKK-mediated degradation of IB. Genetic inhibition of
the IKK/NF-B/MuRF1 pathway or through pharmacolog-
ical therapeutics, such as salicylates to inhibit IKK activ-
ity, rescues the skeletal muscle-wasting phenotype (37,
39,40). In the current study, skeletal muscle morphology
was not altered by either TNF- exposure or siRNA-
mediated gene silencing of IKK. However, our experi-
ments were limited to a short-term (ﬁrst phase) TNF-
exposure, and we did not directly test whether IKK
siRNA would modify culture growth in the presence of a
long-term (second phase) TNF- exposure.
TNF- directly induces skeletal muscle insulin resis-
tance in vivo in healthy humans (1) and rodents (41,42)
and in vitro in cultured myotubes (22). Although the role of
TNF- in the development of skeletal muscle insulin
resistance in type 2 diabetic patients remains unresolved,
current evidence suggests that IKK may be an interme-
diate kinase through which TNF- and other inﬂammatory
processes induce skeletal muscle insulin resistance (5,
6,35). IKK activation has been closely linked to the
development and pathogenesis of insulin resistance
(20,21). Pharmacological inhibition of IKK activity im-
proves insulin-mediated glucose metabolism (3,20,21),
even in insulin-resistant obese, nondiabetic individuals
(43). Increased expression of IKK has been noted in
omental fat from obese humans, potentially contributing
to differential roles of omental and subcutaneous fat in the
pathophysiology of obesity (44).
Studies linking IKK and skeletal muscle insulin resis-
tance in rodents have yielded conﬂicting results. Pharma-
cological IKK inhibition ameliorated insulin resistance
and upregulated plasma levels of adiponectin in KKAy
mice fed a high-fat diet (45). Heterozygous IKK

/ mice
fed a high-fat diet or intergressed on an obese ob/ob mice
background were protected against the development of
insulin resistance (3). Conversely, mice with either skele-
tal muscle–speciﬁc IKK knockout or a separate cohort of
heterozygous IKK

/ were not protected against gold
thioglucose–induced obesity or dietary-induced metabolic
abnormalities (46). The reason for the differences noted
between these animal models is unknown, but the differ-
ences could be strain speciﬁc or related to undeﬁned
experimental differences.
TNF- exposure leads to activation of two separate
transcription factor–signaling pathways, namely the IKK
and JNK pathways, which are linked to proinﬂammatory
responses associated with obesity and insulin resistance
(47). Here, we show that siRNA-mediated gene silencing of
IKK prevented TNF-–induced insulin resistance on glu-
cose uptake and metabolism in cultured myotubes, with a
concomitant increase in phosphorylation of Akt (at Ser
473,
Thr
308), and AS160. Inhibition of ERK signaling using
pharmacological inhibitor PD98059 did not alter TNF-–
mediated reduction in insulin-stimulated glycogen synthe-
sis. Furthermore, the TNF-–mediated activation of ERK
and JNK was unaffected by the siRNA-mediated reduction
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FIG. 8. Effect of siRNA-mediated silencing of IKK on IRS-1 Ser
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phosphorylation. Representative immunoblot showing IRS-1 migration
on SDS-PAGE (A) or IRS-1 Ser
312 phosphorylation (B). IRS-1 Ser
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untransfected controls. Arrow highlights mobility shift (A)( n  4).
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IKK did not prevent TNF-–induced IRS-1 serine phos-
phorylation on Ser
312 or the IRS-1 mobility shift as deter-
mined by SDS-PAGE. This is in contrast to some reports
indicating that inhibition of IKK prevents IRS-1 Ser
307
(equivalent to human IRS-1 Ser
312) phosphorylation in
cultured HEPG2, 3T3-L1 adipocytes, or embryonic kidney
cells (25,26,48) but is consistent with other observations
that IKK is disassociated from IRS-1 phosphorylation
(Steven E. Shoelson, Joslin Diabetes Center, Boston, MA,
personal communication). Our results indicate that the
TNF- effect on IRS-1 serine phosphorylation is primarily
mediated via parallel IKK independent pathways, such as
JNK.
IKK silencing fully restored the TNF-–mediated re-
duction of insulin-stimulated glucose metabolism, despite
modest impairments in insulin signaling at the level of Akt.
However, TNF- exposure was associated with a profound
impairment in insulin-stimulated AS160 phosphorylation,
which was restored following IKK silencing. Since AS160
is a critical step in the processes involved from insulin
signaling to glucose transport, this may explain the en-
hanced glucose metabolism in IKK-depleted myotubes.
Our results may also indicate that a relatively small pool of
total Akt is critical for signaling to AS160, and this pool
may be highly sensitive to TNF-, possibly due to cellular
localization.
In primary cultures of human muscle, TNF- exposure
enhanced phosphorylation of GSK3. This ﬁnding is con-
sistent with a ﬁnding of a previous study in HEK293 cells
and mouse embryonic ﬁbroblasts (49), where TNF-–
mediated activation of ERK was partly dependent on
GSK3 phosphorylation. Conversely, TNF- exposure has
also been shown to prevent insulin-stimulated phosphor-
ylation of GSK3 in HEPG2 cells (50). Here, we report that
IKK silencing prevents the TNF-–mediated increase in
GSK3 phosphorylation; however, the functional conse-
quence requires further investigation. Although GSK3
Ser
9 phosphorylation has been linked to a reduction in the
constitutive ability of GSK3 to phosphorylate Ser
641 of
glycogen synthase, it does not completely abolish the
ability of GSK3 to phosphorylate glycogen synthase (51).
Thus, further studies are warranted to establish whether
GSK3 activity is modulated.
MAP4K4 is a member of the NCK interacting kinase
family (23). NCK interacting kinase family kinases are
potent activators of the IKK complex and activators of
ERK and JNK (34), which suggests that MAP4K4 is likely
to be an upstream regulator of IKK. Here, we show that
siRNA-mediated silencing of IKK had no effect on expres-
sion of MAP4K4, excluding a negative feedback on this
upstream kinase. We have previously reported that the
siRNA-mediated reduction of MAP4K4 rescues TNF-–
mediated insulin resistance in primary human skeletal
muscle cultures (22), consistent with our present ﬁndings
for IKK. Although a reduction of either MAP4K4 or IKK
prevents the effect of TNF- on insulin-mediated glucose
uptake and metabolism, the reduction of MAP4K4 also
prevented IRS-1 serine phosphorylation and signaling to
ERK 1/2 and JNK. In contrast, siRNA silencing of IKK did
not alter TNF- signaling to either IRS-1 Ser
312, JNK, or
ERK phosphorylation. These results are consistent with
the hypothesis that downstream signals from MAP4K4
diverge toward an ERK/JNK pathway that mediates effects
on IRS-1 serine phosphorylation and an IKK pathway that
mediates effects on glucose uptake and metabolism.
In summary, targeted deletion of IKK using siRNA
prevents TNF-–mediated insulin resistance on Akt and
AS160 phosphorylation and glucose uptake and metabo-
lism in human skeletal muscle. These results underscore
IKK as a potential therapeutic target to prevent periph-
eral insulin resistance.
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